Develop and commercialize pain management medications. Offer abuse-deterrent opioid formulations. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
Average growth of 30% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 11.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 96% of them.
Analysts' average target sits 108% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 30% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 23/100. For a turnaround signal, the stock first needs to close the gap with the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 32/100.
On our five-subject report card, COLL sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: COLL is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.